secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001140361-24-030447
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis expands Otsuka license for donidalorsen in Asia-Pacific; $20M upfront
---------------------------------------------------------------------------

- Otsuka gains exclusive rights to commercialize donidalorsen (HAE) in Asia-Pacific; Ionis retains US rights.
- Ionis receives $20M upfront, plus milestone payments and tiered royalties similar to the Europe deal.
- Ionis plans to file U.S. NDA for donidalorsen in 2024 and launch independently if approved.
- Otsuka will handle Asia-Pacific and Europe regulatory filings and commercialization; Ionis leads global development.
- Positive Phase 3 OASIS-HAE and OASISplus results were recently published in NEJM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/0001140361-24-030447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124030447/ef20031301_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-030447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer